Drug Profile
GCSB 5
Alternative Names: GCSB; GCSB-5; ShinbaroLatest Information Update: 01 Apr 2022
Price :
$50
*
At a glance
- Originator Green Cross
- Developer GC Biopharma
- Class Analgesics; Anti-inflammatories; Antirheumatics; Herbal medicines
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Osteoarthritis
Most Recent Events
- 29 Mar 2022 GC Pharma is now called GC Biopharma
- 26 Jul 2013 Seoul National University Hospital & Green Cross plan a phase II/III trial for Osteoarthritis in South Korea (NCT01910116)
- 01 Sep 2011 Launched for Osteoarthritis in South Korea (PO)